Roseman Bioventures is entering its next phase of growth with the appointment of Titus Plattel, MSc., MBA, as Managing Director, bringing more than three decades of biotechnology and life sciences leadership experience to Nevada’s growing innovation ecosystem.
Plattel will oversee the strategic direction and operational expansion of Roseman Bioventures, Roseman University of Health Sciences’ 120,000-square-foot life sciences incubator in Las Vegas. His appointment comes as the organization continues to attract innovative early- and mid-stage companies and build the infrastructure, partnerships and resources needed to accelerate scientific discoveries toward commercialization.
Plattel brings extensive experience leading emerging biotechnology companies, including service as CEO and COO of multiple high-growth private companies. He has also held strategic leadership and commercial positions with major life sciences companies including Biogen, Amgen and Bavarian Nordic.
“Titus brings a wealth of industry expertise and a forward-thinking operational approach that perfectly align with our mission to create a capital-efficient, highly collaborative life-science ecosystem in Nevada,” said Jeffery Talbot, PhD, Vice President for Research at Roseman University and co-founder of Roseman Bioventures.
Plattel’s arrival coincides with growing momentum at Roseman Bioventures and across Southern Nevada’s emerging life sciences sector.
New Companies, New Momentum
Among the latest companies to establish operations at Roseman Bioventures is Nautilus X-Ray, a medical imaging startup developing the next generation of computed tomography technology.
The company selected Roseman Bioventures in part because of its existing specialized infrastructure, including an X-ray facility that allows Nautilus to avoid the substantial cost and time required to build one from the ground up. From its new Las Vegas location, the company plans to expand its research and development, engineering and precision manufacturing teams while advancing its ultra-fast CT platform toward clinical use.
The arrival of Nautilus X-Ray follows significant progress by other Roseman Bioventures resident companies.
Infiltrate Bio, for example, recently published research in Science Translational Medicine and was selected for Palantir’s Startup Fellowship Cohort #002, providing the company with access to Palantir’s Artificial Intelligence Platform and specialized engineering support.
For Plattel, developments like these demonstrate the potential of the Roseman Bioventures model.
“Startups no longer need to compromise between premier facilities and financial runway,” Plattel said. “Our mission is to provide the cutting-edge tools, institutional credibility and life science networks that empower our resident teams to hit critical scientific and clinical milestones faster.”
Building a Life Sciences Ecosystem in Nevada
Roseman Bioventures was created to address one of the most persistent challenges facing emerging life sciences companies: moving promising discoveries from research toward viable products, technologies and therapies.
Its Las Vegas facility provides turnkey laboratory and research space, flexible infrastructure and access to an expanding network of academic, industry, investment and community partners. By reducing the capital required to establish sophisticated research operations, Roseman Bioventures allows companies to direct more of their resources toward science, product development and commercialization.
That approach is also helping position Nevada as an increasingly attractive destination for biotechnology, medical technology and other life sciences ventures.
Under Plattel’s leadership, Roseman Bioventures will continue expanding its incubator model while laying the groundwork for a future venture studio, designed to help build promising life sciences companies from their earliest stages.
The vision extends beyond providing laboratory space. Roseman Bioventures aims to create an environment where entrepreneurs, scientists, investors, healthcare organizations and academic researchers can work together to advance innovations that improve human health while contributing to the continued diversification of Nevada’s economy.
Plattel’s appointment represents another important step toward that goal and toward establishing Southern Nevada as a place where life sciences companies can not only launch, but grow and thrive.
No responses yet